<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01593787</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696A1304</org_study_id>
    <nct_id>NCT01593787</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction</brief_title>
  <official_title>A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assessed the safety, tolerability, and efficacy of LCZ696 in hypertensive patients
      with renal dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Reported Adverse Events (Total Adverse Events, Serious Adverse Events and Death)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of patients with total adverse events, serious adverse events and death were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 8</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Sitting BP measurements were performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at Week 8</measure>
    <time_frame>baseline, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Successful BP Control at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>A successful BP control was defined as msSBP &lt;130 mmHg and msDBP &lt;80 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SBP Control at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>SBP control was defined as msSBP &lt;130 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DBP Control at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>DBP control was defined as msDBP &lt;80 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Successful Response Rate in msSBP at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>Successful response rate was defined as msSBP &lt;130 mmHg or a reduction of ≥20 mmHg from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Successful Response Rate in msDBP at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>Successful response rate was defined as msDBP &lt;80 mmHg or a reduction of ≥10 mmHg from baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hypertension With Renal Dysfunction</condition>
  <arm_group>
    <arm_group_label>LCZ696 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants were started on LCZ696 100 mg once daily on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCZ696 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCZ696 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <description>100 mg, 200 mg, 400 mg tablets.</description>
    <arm_group_label>LCZ696 100 mg</arm_group_label>
    <arm_group_label>LCZ696 200 mg</arm_group_label>
    <arm_group_label>LCZ696 400 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal findings: Hypertensive patients with renal dysfunction and stable renal
             condition at least 4 weeks before screening visit.

          -  Satisfy office msSBP ≥140 mmHg and &lt;180 mmHg at baseline.

        Exclusion Criteria:

          -  Patients show msDBP ≥110 mmHg and/or msSBP ≥180 mmHg.

          -  History of angioedema, drug-related or otherwise, as reported by the patient.

          -  Any other following renal disorder:

          -  Patients show eGFR &lt; 15mL/min/1.73m^2

          -  Patients on dialysis

          -  Patients who previously entered a LCZ696 study and had been randomized or enrolled
             into the active drug treatment epoch.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido</state>
        <zip>063-0842</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>003-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>003-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aira-city</city>
        <state>Kagoshima</state>
        <zip>899-5431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawasaki-city</city>
        <state>Kanagawa</state>
        <zip>210-0852</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>231-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sendai-city</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>701-0192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fujimino</city>
        <state>Saitama</state>
        <zip>356-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hachioji-city</city>
        <state>Tokyo</state>
        <zip>192-0918</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>108-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <zip>536-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Ito S, Satoh M, Tamaki Y, Gotou H, Charney A, Okino N, Akahori M, Zhang J. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens Res. 2015 Apr;38(4):269-75. doi: 10.1038/hr.2015.1. Epub 2015 Feb 19.</citation>
    <PMID>25693859</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2012</study_first_submitted>
  <study_first_submitted_qc>May 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2012</study_first_posted>
  <results_first_submitted>July 8, 2015</results_first_submitted>
  <results_first_submitted_qc>August 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 13, 2015</results_first_posted>
  <last_update_submitted>August 7, 2015</last_update_submitted>
  <last_update_submitted_qc>August 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Renal dysfunction</keyword>
  <keyword>LCZ696</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LCZ696 100 mg</title>
          <description>All participants were started on LCZ696 100 mg once daily on day 1.</description>
        </group>
        <group group_id="P2">
          <title>LCZ696 200 mg</title>
          <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.</description>
        </group>
        <group group_id="P3">
          <title>LCZ696 400 mg</title>
          <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LCZ696 100 mg</title>
          <description>All participants were started on LCZ696 100 mg once daily on day 1.</description>
        </group>
        <group group_id="B2">
          <title>LCZ696 200 mg</title>
          <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.</description>
        </group>
        <group group_id="B3">
          <title>LCZ696 400 mg</title>
          <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.0" spread="5.10"/>
                    <measurement group_id="B2" value="71.3" spread="8.80"/>
                    <measurement group_id="B3" value="62.3" spread="9.04"/>
                    <measurement group_id="B4" value="65.8" spread="9.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Reported Adverse Events (Total Adverse Events, Serious Adverse Events and Death)</title>
        <description>Percentage of patients with total adverse events, serious adverse events and death were reported.</description>
        <time_frame>8 weeks</time_frame>
        <population>Safety Set: This set included all participants who received at least one dose of LCZ696. AE analysis was determined by actual treatment, i.e. the LCZ696 dose on the day in which the corresponding summary was targeting. Other safety analysis was determined by the maximum treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.</description>
          </group>
          <group group_id="O4">
            <title>Total LCZ696</title>
            <description>All participants who received LCZ696</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Reported Adverse Events (Total Adverse Events, Serious Adverse Events and Death)</title>
          <description>Percentage of patients with total adverse events, serious adverse events and death were reported.</description>
          <population>Safety Set: This set included all participants who received at least one dose of LCZ696. AE analysis was determined by actual treatment, i.e. the LCZ696 dose on the day in which the corresponding summary was targeting. Other safety analysis was determined by the maximum treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse events (serious and non-serious)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 8</title>
        <description>Sitting BP measurements were performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurements.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>Full Analysis Set (FAS): This set included all participants who entered the treatment epoch. Patients who were not qualified to enter the treatment epoch were excluded from the FAS provided those participants did not receive LCZ696.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.</description>
          </group>
          <group group_id="O4">
            <title>Total LCZ696</title>
            <description>All participants who received LCZ696</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 8</title>
          <description>Sitting BP measurements were performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurements.</description>
          <population>Full Analysis Set (FAS): This set included all participants who entered the treatment epoch. Patients who were not qualified to enter the treatment epoch were excluded from the FAS provided those participants did not receive LCZ696.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.71" spread="12.314"/>
                    <measurement group_id="O2" value="-27.19" spread="10.557"/>
                    <measurement group_id="O3" value="-17.79" spread="10.701"/>
                    <measurement group_id="O4" value="-20.50" spread="11.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at Week 8</title>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.</description>
          </group>
          <group group_id="O4">
            <title>Total LCZ696</title>
            <description>All participants who received LCZ696</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at Week 8</title>
          <population>FAS</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.17" spread="4.690"/>
                    <measurement group_id="O2" value="-9.94" spread="7.557"/>
                    <measurement group_id="O3" value="-7.99" spread="6.385"/>
                    <measurement group_id="O4" value="-8.32" spread="6.308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Successful BP Control at Week 8</title>
        <description>A successful BP control was defined as msSBP &lt;130 mmHg and msDBP &lt;80 mmHg</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.</description>
          </group>
          <group group_id="O4">
            <title>Total LCZ696</title>
            <description>All participants who received LCZ696</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Successful BP Control at Week 8</title>
          <description>A successful BP control was defined as msSBP &lt;130 mmHg and msDBP &lt;80 mmHg</description>
          <population>FAS</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="37.5"/>
                    <measurement group_id="O3" value="5.6"/>
                    <measurement group_id="O4" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving SBP Control at Week 8</title>
        <description>SBP control was defined as msSBP &lt;130 mmHg.</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.</description>
          </group>
          <group group_id="O4">
            <title>Total LCZ696</title>
            <description>All participants who received LCZ696</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SBP Control at Week 8</title>
          <description>SBP control was defined as msSBP &lt;130 mmHg.</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DBP Control at Week 8</title>
        <description>DBP control was defined as msDBP &lt;80 mmHg.</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.</description>
          </group>
          <group group_id="O4">
            <title>Total LCZ696</title>
            <description>All participants who received LCZ696</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DBP Control at Week 8</title>
          <description>DBP control was defined as msDBP &lt;80 mmHg.</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Successful Response Rate in msSBP at Week 8</title>
        <description>Successful response rate was defined as msSBP &lt;130 mmHg or a reduction of ≥20 mmHg from baseline</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.</description>
          </group>
          <group group_id="O4">
            <title>Total LCZ696</title>
            <description>All participants who received LCZ696</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Successful Response Rate in msSBP at Week 8</title>
          <description>Successful response rate was defined as msSBP &lt;130 mmHg or a reduction of ≥20 mmHg from baseline</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Successful Response Rate in msDBP at Week 8</title>
        <description>Successful response rate was defined as msDBP &lt;80 mmHg or a reduction of ≥10 mmHg from baseline.</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP &lt;80 mmHg and msSBP &lt;130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.</description>
          </group>
          <group group_id="O4">
            <title>Total LCZ696</title>
            <description>All participants who received LCZ696</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Successful Response Rate in msDBP at Week 8</title>
          <description>Successful response rate was defined as msDBP &lt;80 mmHg or a reduction of ≥10 mmHg from baseline.</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="87.5"/>
                    <measurement group_id="O3" value="61.1"/>
                    <measurement group_id="O4" value="71.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LCZ 100 mg</title>
          <description>LCZ 100 mg</description>
        </group>
        <group group_id="E2">
          <title>LCZ 400 mg</title>
          <description>LCZ 400 mg</description>
        </group>
        <group group_id="E3">
          <title>Total LCZ696</title>
          <description>All participants who received LCZ696</description>
        </group>
        <group group_id="E4">
          <title>LCZ 200 mg</title>
          <description>LCZ 200 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>SUPRAVENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>+1 (862) 778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

